PPIB and chronic hepatitis C virus infection: PPIase activity was also found involved in HCV replication cycle and led to the development of a series of cyclophilin inhibitors such as NIM811, DEBIO-025 (Alisporivir) and SCY-635, which have demonstrated anti-HCV activity in patients in the absence of toxicity, identifying cyclophilins as therapeutic target for chronic hepatitis C [121–126].